Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Urogen Pharma (NASDAQ:URGN) Stock Rating Upgraded by Wall Street Zen  MarketBeat

Urogen Pharma (NASDAQ:URGN) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Click here to get full coverage on Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates  Yahoo Finance

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)  simplywall.st

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st

Click here to get full coverage on $URGN stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

$URGN stock is down 11% today. Here's what we see in our data.  Quiver Quantitative

$URGN stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Urogen Pharma (URGN) general counsel sells $29k in shares - Investing.com

Urogen Pharma (URGN) general counsel sells $29k in shares  Investing.com

Urogen Pharma (URGN) general counsel sells $29k in shares - Investing.com

Click here to get full coverage on URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit  PR Newswire

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire

Click here to get full coverage on Biotech Leader UroGen Pharma Announces Triple Conference Schedule: Wells Fargo, Cantor, H.C. Wainwright - Stock Titan

Biotech Leader UroGen Pharma Announces Triple Conference Schedule: Wells Fargo, Cantor, H.C. Wainwright  Stock Titan

Biotech Leader UroGen Pharma Announces Triple Conference Schedule: Wells Fargo, Cantor, H.C. Wainwright - Stock Titan

Click here to get full coverage on Urogen Pharma $URGN Shares Sold by Trexquant Investment LP - MarketBeat

Urogen Pharma $URGN Shares Sold by Trexquant Investment LP  MarketBeat

Urogen Pharma $URGN Shares Sold by Trexquant Investment LP - MarketBeat

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future - Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future  Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman - PR Newswire

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman  PR Newswire

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman - PR Newswire

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Shares Down 8% Following Insider Selling - MarketBeat

Urogen Pharma (NASDAQ:URGN) Shares Down 8% Following Insider Selling  MarketBeat

Urogen Pharma (NASDAQ:URGN) Shares Down 8% Following Insider Selling - MarketBeat

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Insider Sells $16,644.81 in Stock - MarketBeat

Urogen Pharma (NASDAQ:URGN) Insider Sells $16,644.81 in Stock  MarketBeat

Urogen Pharma (NASDAQ:URGN) Insider Sells $16,644.81 in Stock - MarketBeat

Click here to get full coverage on UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates  Yahoo Finance

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 Shares - MarketBeat

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 Shares  MarketBeat

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 Shares - MarketBeat

Click here to get full coverage on UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology - Yahoo Finance

UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology  Yahoo Finance

UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology - Yahoo Finance

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Shares Up 10.6% - Time to Buy? - MarketBeat

Urogen Pharma (NASDAQ:URGN) Shares Up 10.6% - Time to Buy?  MarketBeat

Urogen Pharma (NASDAQ:URGN) Shares Up 10.6% - Time to Buy? - MarketBeat

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Here's Why - MarketBeat

Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Here's Why  MarketBeat

Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Here's Why - MarketBeat

Click here to get full coverage on UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Stock Holdings in Urogen Pharma $URGN - MarketBeat

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Stock Holdings in Urogen Pharma $URGN  MarketBeat

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Stock Holdings in Urogen Pharma $URGN - MarketBeat

Click here to get full coverage on Parkman Healthcare Partners LLC Has $4.35 Million Holdings in Urogen Pharma $URGN - MarketBeat

Parkman Healthcare Partners LLC Has $4.35 Million Holdings in Urogen Pharma $URGN  MarketBeat

Parkman Healthcare Partners LLC Has $4.35 Million Holdings in Urogen Pharma $URGN - MarketBeat

Click here to get full coverage on 67,700 Shares: UroGen Pharma Expands Team with 40 New Hires to Drive Cancer Treatment Portfolio Growth - Stock Titan

67,700 Shares: UroGen Pharma Expands Team with 40 New Hires to Drive Cancer Treatment Portfolio Growth  Stock Titan

67,700 Shares: UroGen Pharma Expands Team with 40 New Hires to Drive Cancer Treatment Portfolio Growth - Stock Titan

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - PR Newswire

Click here to get full coverage on URGN Class Action News: UroGen Pharma Ltd. Investors with - GlobeNewswire

URGN Class Action News: UroGen Pharma Ltd. Investors with  GlobeNewswire

URGN Class Action News: UroGen Pharma Ltd. Investors with - GlobeNewswire

Click here to get full coverage on $URGN stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

$URGN stock is up 11% today. Here's what we see in our data.  Quiver Quantitative

$URGN stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking  simplywall.st

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st

Click here to get full coverage on UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha

UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN)  Seeking Alpha

UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire

UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT  GlobeNewswire

UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire

Click here to get full coverage on New Analyst Forecast: $URGN Given $16.0 Price Target - Nasdaq

New Analyst Forecast: $URGN Given $16.0 Price Target  Nasdaq

New Analyst Forecast: $URGN Given $16.0 Price Target - Nasdaq

Click here to get full coverage on Market Leaders: Why is URGN stock going up - 2025 Short Interest & AI Driven Price Predictions - خودرو بانک

Market Leaders: Why is URGN stock going up - 2025 Short Interest & AI Driven Price Predictions  خودرو بانک

Market Leaders: Why is URGN stock going up - 2025 Short Interest & AI Driven Price Predictions - خودرو بانک

Click here to get full coverage on UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN)  Seeking Alpha

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on Urogen Pharma $URGN Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat

Urogen Pharma $URGN Shares Sold by Adage Capital Partners GP L.L.C.  MarketBeat

Urogen Pharma $URGN Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat

Click here to get full coverage on URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit  PR Newswire

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $URGN Given $36.0 Price Target - Quiver Quantitative

New Analyst Forecast: $URGN Given $36.0 Price Target  Quiver Quantitative

New Analyst Forecast: $URGN Given $36.0 Price Target - Quiver Quantitative

Click here to get full coverage on US Stocks Recap: What is the target price for URGN stock - 2025 Momentum Check & Real-Time Buy Signal Alerts - خودرو بانک

US Stocks Recap: What is the target price for URGN stock - 2025 Momentum Check & Real-Time Buy Signal Alerts  خودرو بانک

US Stocks Recap: What is the target price for URGN stock - 2025 Momentum Check & Real-Time Buy Signal Alerts - خودرو بانک

Click here to get full coverage on Dividend Watch: Is URGN stock a good pick for beginners - 2025 Major Catalysts & Weekly Momentum Picks - خودرو بانک

Dividend Watch: Is URGN stock a good pick for beginners - 2025 Major Catalysts & Weekly Momentum Picks  خودرو بانک

Dividend Watch: Is URGN stock a good pick for beginners - 2025 Major Catalysts & Weekly Momentum Picks - خودرو بانک

Click here to get full coverage on UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results - Yahoo Finance

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results  Yahoo Finance

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results - Yahoo Finance

Click here to get full coverage on Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week - Benzinga

Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week  Benzinga

Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week - Benzinga

Click here to get full coverage on Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Buy" by Brokerages - MarketBeat

Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Buy" by Brokerages  MarketBeat

Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Buy" by Brokerages - MarketBeat

Click here to get full coverage on Investors who lost money on UroGen Pharma Ltd.(URGN) should - GlobeNewswire

Investors who lost money on UroGen Pharma Ltd.(URGN) should  GlobeNewswire

Investors who lost money on UroGen Pharma Ltd.(URGN) should - GlobeNewswire

Click here to get full coverage on INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLC - GlobeNewswire

INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLC  GlobeNewswire

INVESTOR ALERT: Investigation of UroGen Pharma Ltd. (URGN) Announced by Holzer & Holzer, LLC - GlobeNewswire

Click here to get full coverage on H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - Yahoo Finance

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy  Yahoo Finance

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - Yahoo Finance

Click here to get full coverage on UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire

UroGen Pharma Ltd. (URGN) Faces Securities Class Action  GlobeNewswire

UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire

Click here to get full coverage on UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors - GlobeNewswire

UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors  GlobeNewswire

UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors - GlobeNewswire

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Click here to get full coverage on UroGen Pharma Q2 2025 Earnings: How to Access Live Results and Investor Call August 7 - Stock Titan

UroGen Pharma Q2 2025 Earnings: How to Access Live Results and Investor Call August 7  Stock Titan

UroGen Pharma Q2 2025 Earnings: How to Access Live Results and Investor Call August 7 - Stock Titan

Click here to get full coverage on UroGen’s revenue set to double by 2026 on bladder cancer drug rollout - S&P Global

UroGen’s revenue set to double by 2026 on bladder cancer drug rollout  S&P Global

UroGen’s revenue set to double by 2026 on bladder cancer drug rollout - S&P Global

Click here to get full coverage on URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for - GlobeNewswire

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for  GlobeNewswire

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for - GlobeNewswire

Click here to get full coverage on URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with - GlobeNewswire

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with  GlobeNewswire

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with - GlobeNewswire

Click here to get full coverage on UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | U - GuruFocus

UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | U  GuruFocus

UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | U - GuruFocus

Click here to get full coverage on UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation (NASDAQ:URGN) - Seeking Alpha

UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation (NASDAQ:URGN)  Seeking Alpha

UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - Business Wire

Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm  Business Wire

Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - Business Wire

Click here to get full coverage on Urogen Pharma (URGN) general counsel sells $29k in shares By Investing.com - Investing.com Australia

Urogen Pharma (URGN) general counsel sells $29k in shares By Investing.com  Investing.com Australia

Urogen Pharma (URGN) general counsel sells $29k in shares By Investing.com - Investing.com Australia

Click here to get full coverage on UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Receives Consistent Buy Rating from Analyst | URGN Stock News - GuruFocus

Click here to get full coverage on UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ) - Seeking Alpha

UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ)  Seeking Alpha

UroGen stock falls as cancer drug is rebuked (URGN:NASDAQ) - Seeking Alpha

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN - PR Newswire

Click here to get full coverage on UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:URGN) 2025-08-09 - Seeking Alpha

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:URGN) 2025-08-09  Seeking Alpha

UroGen Pharma Ltd. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:URGN) 2025-08-09 - Seeking Alpha

Click here to get full coverage on URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd. - GlobeNewswire

URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd.  GlobeNewswire

URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd. - GlobeNewswire

Click here to get full coverage on URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for - GlobeNewswire

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for  GlobeNewswire

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for - GlobeNewswire

Click here to get full coverage on Urogen Pharma (URGN) general counsel sells $29k in shares By Investing.com - Investing.com UK

Urogen Pharma (URGN) general counsel sells $29k in shares By Investing.com  Investing.com UK

Urogen Pharma (URGN) general counsel sells $29k in shares By Investing.com - Investing.com UK

Click here to get full coverage on 3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends  MarketBeat

3 Bullish Biotech Stocks With Explosive Growth Trends - MarketBeat

Click here to get full coverage on Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt - GuruFocus

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt  GuruFocus

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt - GuruFocus

Click here to get full coverage on URGN Gains Upgrade Following FDA Approval for Zusduri | URGN Stock News - GuruFocus

URGN Gains Upgrade Following FDA Approval for Zusduri | URGN Stock News  GuruFocus

URGN Gains Upgrade Following FDA Approval for Zusduri | URGN Stock News - GuruFocus

Click here to get full coverage on URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm  PR Newswire

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Click here to get full coverage on What's Going On With UroGen Pharma Stock Wednesday? - Benzinga

What's Going On With UroGen Pharma Stock Wednesday?  Benzinga

What's Going On With UroGen Pharma Stock Wednesday? - Benzinga

Click here to get full coverage on Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm - GlobeNewswire

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm  GlobeNewswire

Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDQ: URGN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm - GlobeNewswire

Click here to get full coverage on Rosen Law Firm Urges UroGen Pharma Ltd. (NASDAQ: URGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire

Rosen Law Firm Urges UroGen Pharma Ltd. (NASDAQ: URGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights  Business Wire

Rosen Law Firm Urges UroGen Pharma Ltd. (NASDAQ: URGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire

UroGen Pharma Ltd (URGN)

Price Chart

Key Statistics

Technicals

About URGN

Latest News

Urogen Pharma (NASDAQ:URGN) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st

Advanced Charts

Top Gainers

Top Losers